Biotech RadarJobs updated

COMPANY

Humacyte

HQ: Durham, NC source · humacyte.com ↗ · Southeast

FDA-approved therapeutic company Clinical Phase 3

12 open jobs · last seen Oct 23, 2026 · 30 sources

Location: Durham, NC · source · Oct 14, 2026

Keywords: Renal Failure End Stage Renal Disease Hemodialysis Vascular Access Peripheral Vascular Disease Arterial Injury Trauma Injury Trauma Chronic Kidney Failure Vascular Diseases End Stage Renal Disease on Dialysis Vascular Injury Vascular Trauma Arterial Bleeding Vascular System Injury Coronary Artery Disease Vascular System Injuries Peripheral Artery Disease Multiple Trauma Trauma Blunt Peripheral Arterial Disease Acellular Tissue Engineered Vessel Human Acellular Vessel HAV implantation Acellular Tissue Engineered Vessel (Symvess) Humacyte Coronary Tissue Engineered Vessel (CTEV) Acellular Tissue Engineered Vessel (ATEV) / Human Acellular Vessel (HAV)

12Open jobs$195.0MRaised (2 yrs)15Trials (company is sponsor)1FDA records (2 yrs)10NIH grants

Hiring

TitleLocation (from posting)Employer postedFirst seen
Maintenance EngineerNorth Carolina, Durham, NC, USOct 22, 2026Oct 11, 2026
Senior Mechanical TechnicianNorth Carolina, Durham, NC, USOct 22, 2026Oct 11, 2026
Warehouse Logistics Associate INorth Carolina, Durham, NC, USOct 21, 2026Oct 22, 2026
(Sr.) Manager, Marketing Communications & DTCRemote, USOct 21, 2026Oct 21, 2026
MSAT Engineer IINorth Carolina, Durham, NC, USOct 16, 2026Oct 16, 2026

See all 12 jobs

Timeline

  1. Trial start Phase 4: Multicenter Study to Evaluate the Safety and Efficacy of SYMVESS™ in a Real World Setting in Patients With Extremity Arterial Injury Requiring Urgent Repair source ↗
  2. Trial start Phase 3: An Open-label Study to Assess the Safety and Efficacy of SYMVESS® as a Vascular Conduit in Adolescents With Extremity Arterial Injury. source ↗
  3. Trial start Phase 2: Study to Evaluate the Safety and Efficacy of Humacyte's Coronary Tissue Engineered Vessel (CTEV) in Patients With Coronary Artery Disease Requiring Coronary Artery Bypass Grafting (CABG) source ↗
  4. Raise Follow-on offering: $50M (total, as published), announced Jun 10, 2026. Source: SEC filing. source ↗
  5. Raise Follow-on offering — Registered direct: $20M (total, as published), announced Mar 19, 2026. Source: SEC filing. source ↗
  6. Debt Debt financing: $77.5M (up to, as announced), announced Dec 16, 2025. Source: company release on GlobeNewswire. source ↗
  7. Raise Follow-on offering — Registered direct: $60M (total, as published), announced Oct 7, 2025. Source: company release on GlobeNewswire. source ↗
  8. Raise Follow-on offering: $50M (total, as published), announced Mar 26, 2025. Source: company release on GlobeNewswire. source ↗
  9. FDA FDA New drug/biologic (novel): symvess (acellular tissue engineered vessel-tyod) — BLA125812, Dec 19, 2024. Applicant at approval: Humacyte Global, Inc. source ↗
  10. Raise Follow-on offering — Registered direct: $15M (total, as published), announced Nov 14, 2024. Source: company release on GlobeNewswire. source ↗
  11. Trial start Phase 3: To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis source ↗
  12. Trial start —: An Observational Study to Evaluate the Safety and Efficacy of Humacyte's HAV for Arterial Replacement or Reconstruction in Ukrainian Patients With Life or Limb-threatening Vascular Trauma source ↗
  13. Trial start Phase 2: Safety and Efficacy Assessment of HAV in Patients Needing Vascular Access for Dialysis source ↗
  14. Trial start Phase 2/Phase 3: Humacyte Acellular Tissue Engineered Vessel (ATEV) in Patients With Vascular Trauma source ↗
  15. Trial start Phase 3: Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis source ↗
  16. Trial start Phase 2: Humacyte's HAV for Femoro-Popliteal Bypass in Patients With PAD source ↗
  17. Trial start Phase 3: Comparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for Hemodialysis source ↗
  18. Trial start Not phased (device or behavioral study): Evaluation of the Safety and Efficacy of a Vascular Prosthesis as an Above-Knee Bypass Graft in Patients With PAD source ↗
  19. Trial start Phase 1: Safety and Efficacy of a Vascular Prosthesis for Hemodialysis Access in Patients With End-Stage Renal Disease source ↗
  20. Trial start Not phased (device or behavioral study): Evaluation of the Safety and Efficacy of a Vascular Prosthesis for Hemodialysis Access in Patients With ESRD source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $195.0M · Debt: $77.5M. Last 2 years.

Clinical trials (lead sponsor) 15

RecordTitlePhaseStatusStartPrimary completion
NCT07141641Individual Patient Expanded Access for Acellular Tissue Engineered Vessel (ATEV) for Vascular Disease and Dialysis AccessNot listedTemporarily not availableNot listedNot listed
NCT02644941Comparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for HemodialysisPhase 3CompletedMay 24, 20162019-05 (actual)
NCT07762794Multicenter Study to Evaluate the Safety and Efficacy of SYMVESS™ in a Real World Setting in Patients With Extremity Arterial Injury Requiring Urgent RepairPhase 4Not yet recruiting2026-092030-09 (estimated)
NCT07762313An Open-label Study to Assess the Safety and Efficacy of SYMVESS® as a Vascular Conduit in Adolescents With Extremity Arterial Injury.Phase 3Not yet recruiting2026-092028-12 (estimated)
NCT03005418Humacyte Acellular Tissue Engineered Vessel (ATEV) in Patients With Vascular TraumaPhase 2/Phase 3CompletedSep 1, 2018Sep 19, 2023 (actual)
NCT07730528Study to Evaluate the Safety and Efficacy of Humacyte's Coronary Tissue Engineered Vessel (CTEV) in Patients With Coronary Artery Disease Requiring Coronary Artery Bypass Grafting (CABG)Phase 2Not yet recruiting2026-092030-09 (estimated)
NCT05908084To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring HemodialysisPhase 3Active, not recruitingSep 7, 20232027-06 (estimated)
NCT03183245Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for HemodialysisPhase 3CompletedSep 29, 2017Apr 22, 2024 (actual)
NCT03631056Individual Patient Expanded Access for Acellular Tissue Engineered Vessel (ATEV) for Vascular System InjuriesNot listedApproved for marketingNot listedNot listed
NCT02887859Humacyte's HAV for Femoro-Popliteal Bypass in Patients With PADPhase 2CompletedDec 20, 20162020-12 (actual)
NCT05873959An Observational Study to Evaluate the Safety and Efficacy of Humacyte's HAV for Arterial Replacement or Reconstruction in Ukrainian Patients With Life or Limb-threatening Vascular TraumaNot listedCompletedMay 1, 2023May 26, 2023 (actual)
NCT01872208Evaluation of the Safety and Efficacy of a Vascular Prosthesis as an Above-Knee Bypass Graft in Patients With PADNot phased (device or behavioral study)CompletedOct 10, 2013May 30, 2016 (actual)
NCT01744418Evaluation of the Safety and Efficacy of a Vascular Prosthesis for Hemodialysis Access in Patients With ESRDNot phased (device or behavioral study)CompletedNov 22, 20122014-12 (actual)
NCT04135417Safety and Efficacy Assessment of HAV in Patients Needing Vascular Access for DialysisPhase 2CompletedNov 12, 2019May 15, 2021 (actual)
NCT01840956Safety and Efficacy of a Vascular Prosthesis for Hemodialysis Access in Patients With End-Stage Renal DiseasePhase 1CompletedMay 23, 2013Apr 28, 2016 (actual)

FDA records (last 2 years)

NIH awards 10

Annual award amounts. Total $6.2M.

Open jobs 12

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Maintenance EngineerNorth Carolina, Durham, NC, USOct 22, 2026Oct 11, 2026Mid
Senior Mechanical TechnicianNorth Carolina, Durham, NC, USOct 22, 2026Oct 11, 2026Senior
Warehouse Logistics Associate INorth Carolina, Durham, NC, USOct 21, 2026Oct 22, 2026Not stated
(Sr.) Manager, Marketing Communications & DTCRemote, USOct 21, 2026Oct 21, 2026Not stated
MSAT Engineer IINorth Carolina, Durham, NC, USOct 16, 2026Oct 16, 2026Not stated
Senior Quality Specialist - QMS & Doc ControlNorth Carolina, Durham, NC, USOct 15, 2026Oct 16, 2026Not stated
Supplier Quality SpecialistNorth Carolina, Durham, NC, USOct 13, 2026Oct 14, 2026Mid
Medical Science LiaisonRemote, US; Minneapolis; Milwaukee; Detroit; ChicagoOct 8, 2026Oct 11, 2026Mid
Senior Demand PlannerDurham, NC, USOct 8, 2026Oct 11, 2026Senior
Manager, Instrumentation & MetrologyNorth Carolina, Durham, NC, USSep 15, 2026Oct 11, 2026Mid
Surgical Sales Executive - NortheastMassachusetts, Boston, MA, US; Connecticut, New Haven, CT, US; Maine, Portland, ME, US; New York, NY, US; Remote, USSep 15, 2026Oct 11, 2026Mid
Surgical Sales Executive- Chicago/MinneapolisRemote, US; Minneapolis; ChicagoSep 15, 2026Oct 11, 2026Mid

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Connect

See your connections at Humacyte on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-12

Feedback